Volatile HDAC Inhibitors for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders, cancers, and other diseases lack effective therapeutics due to challenges in targeting histone deacetylases (HDACs) and crossing the blood-brain barrier, necessitating the development of new HDAC inhibitors that can modulate gene expression and immune responses.
Innovation Solution
The use of volatile compounds, such as diacetyl, which act as HDAC inhibitors, administered as gases or vapors to inhibit HDAC activity, modulate gene expression, and treat or delay the progression of diseases by bypassing the blood-brain barrier through nasal or inhalation routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional HDAC inhibitors are administered orally, then they can modulate gene expression and treat diseases, but they cannot effectively cross the blood-brain barrier to treat neurological disorders
Solution Approach 1:
The patent uses volatile compounds as intermediary carriers that can traverse the blood-brain barrier through inhalation or nasal administration. These volatile HDAC inhibitors act as mediators between the external environment and the central nervous system, enabling drug delivery to brain tissue without requiring traditional oral absorption pathways that are blocked by the blood-brain barrier.
Solution Approach 2:
The patent employs inhalation administration of volatile HDAC inhibitors, utilizing the respiratory system's gas exchange capabilities to deliver active compounds directly to the bloodstream and subsequently to the brain. This pneumatic delivery method bypasses the blood-brain barrier limitation by using the lungs' extensive surface area and rich blood supply as a delivery portal.
2Adaptability or versatility
If new volatile HDAC inhibitors are developed, then they can cross the blood-brain barrier and treat neurological disorders, but the lack of protein targets and difficulty in identifying effective therapeutics remains
Solution Approach 1:
The patent identifies volatile compounds with broad-spectrum HDAC inhibitory activity that can treat multiple disease types including neurological disorders, cancers, and inflammatory conditions. These universal HDAC inhibitors do not require disease-specific protein targets, allowing a single compound to address multiple pathologies through their common epigenetic mechanism of action.
Solution Approach 2:
The patent changes the physical state parameter of HDAC inhibitors from non-volatile to volatile forms, enabling new administration routes and improving brain penetration. This parameter change transforms traditional HDAC inhibitor molecules into inhalable vapors or gases, fundamentally altering their pharmacokinetic properties and therapeutic applicability.
3Reliability
If HDAC inhibitors are used to modulate gene expression, then disease progression can be treated or delayed, but the mechanism involves complex epigenetic regulation that complicates drug development
Solution Approach 1:
The patent extracts and isolates the volatile HDAC inhibitory activity from complex traditional HDAC inhibitor molecules. By identifying small volatile compounds that specifically inhibit HDAC enzymes, the invention separates the essential therapeutic function from the molecular complexity of conventional inhibitors, simplifying drug development while maintaining epigenetic modulation effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Diacetyl and other volatile HDAC inhibitors effectively inhibit HDAC activity, modulate gene expression, and demonstrate potential in treating neurological disorders and cancers by slowing disease progression and improving immune responses, as evidenced by their ability to increase histone acetylation and regulate gene expression in both in vitro and in vivo models.
Implementation Method 1
Histone deacetylases (HDACs) are involved in the regulation of DNA expression. They are implicated in many diseases... HDAC inhibitors are histone-modifying enzymes involved in the removal of acetyl groups from lysine residues and the remodeling of chromatin structure
Data Source
AI summary
Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence, and infectious diseases.